948 Results

People

  1. Kris
    Kris
  2. Kelsen
    Kelsen
  3. Motzer
    Motzer
  4. O'Reilly
    O'Reilly
  5. Saltz
    Saltz
  6. Tyson
    Tyson
  7. Gralla
    Gralla
  8. Hudis
    Hudis
  9. Scher
    Scher
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)
  7. Center for Hematologic Malignancies (109)
  8. Genitourinary Oncology Service (106)
  9. Nursing (101)
  10. Surgery (97)
  1. "vomiting"
Formats
  1. Journal Article (896)
  2. Review (27)
  3. Conference Paper (8)
  4. Editorial (6)
  5. Research Letter (4)
  6. Correspondence (2)
  7. Guidelines (2)
  8. Book Section (1)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)

More Groups

People
  1. Mark Kris (70)
  2. David Kelsen (40)
  3. Robert Motzer (39)
  4. Eileen O'Reilly (30)
  5. Leonard Saltz (30)
  6. Leslie Tyson (28)

More People

Years
  1. 2025 (25)
  2. 2024 (63)
  3. 2023 (44)
  4. 2022 (32)
  5. 2021 (15)
  6. 2020 (50)

More Years

Publications
  1. Journal of Clinical Oncology (90)
  2. Cancer (47)
  3. Clinical Cancer Research (44)
  4. Lancet Oncology (38)
  5. Gynecologic Oncology (31)
  6. Cancer Treatment Reports (26)

More Publications

Publishers
  1. Elsevier Inc. (145)
  2. American Society of Clinical Oncology (92)
  3. Elsevier Science, Inc. (74)
  4. Springer (72)
  5. Oxford University Press (64)
  6. Wiley Blackwell (63)

More Publishers

Results (948)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®)
    Journal Article

    Lee, M. K.; Mitchell, S. A.; Basch, E.; Mazza, G. L.; Langlais, B. T.; Thanarajasingam, G.; Ginos, B. F.; Rogak, L.; Meek, E. A.; Jansen, J.; more...
    Quality of Life Research (2025)

    Fulltext@MSK | Save
  • A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors
    Journal Article

    Schram, A. M.; Boni, V.; Adjei, A. A.; Olszanski, A. J.; Vieito, M.; Francis, J. H.; Kurman, M.; Ahsan, J. M.; Tomkinson, B.; Garralda, E.
    ESMO Open (2025)

    Fulltext@MSK | Save
  • A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors
    Journal Article

    Scott, S. C.; Farago, A.; Lai, W. V.; Zahurak, M.; Rudek, M. A.; Murray, J.; Carducci, M. A.; Uziel, T.; Takebe, N.; Gore, S. D.; more...
    Cancer Chemotherapy and Pharmacology (2025)

    Fulltext@MSK | Save
  • SWOG S1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers
    Journal Article

    Shroff, R. T.; King, G.; Colby, S.; Scott, A. J.; Borad, M. J.; Goff, L.; Matin, K.; Mahipal, A.; Kalyan, A.; Javle, M. M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Clinical outcomes, patterns of failure, and salvage therapies of a large modern cohort of patients with anal squamous cell carcinoma treated with definitive-intent intensity-modulated radiation therapy
    Journal Article

    Roth O'Brien, D. A.; Hristidis, V. C.; Chakrani, Z.; McCann, P.; Damato, A.; Williams, V.; Cote, N.; Reyngold, M.; Rosen, R.; Connell, L.; more...
    International Journal of Radiation Oncology, Biology, Physics (2025)

    Fulltext@MSK | Save
  • Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer
    Journal Article

    Skoulidis, F.; Li, B. T.; Hochmair, M.; Govindan, R.; Vincent, M.; van der Wekken, A. J.; Aransay, N. R.; O’Byrne, K. J.; Girard, N.; Griesinger, F.; more...
    The Oncologist (2025)

    Fulltext@MSK | Save
  • MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
    Journal Article

    Bhutani, M.; Robinson, M.; Foureau, D.; Atrash, S.; Paul, B.; Guo, F.; Grayson, J. M.; Ivanina-Foureau, A.; Pineda-Roman, M.; Varga, C.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • All that can still be done: Communicating with precision and patient-centeredness when recommending hospice initiation for cancer patients
    Editorial

    Epstein, A. S.
    Cancer (2025)

    Fulltext@MSK | Save
  • Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
    Journal Article

    Rathkopf, D. E.; Patel, M. R.; Choudhury, A. D.; Rasco, D.; Lakhani, N.; Hawley, J. E.; Srinivas, S.; Aparicio, A.; Narayan, V.; Runcie, K. D.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: A phase I trial
    Journal Article

    Gounder, M.; Johnson, M.; Heist, R. S.; Shapiro, G. I.; Postel-Vinay, S.; Wilson, F. H.; Garralda, E.; Wulf, G.; Almon, C.; Nabhan, S.; more...
    Nature Communications (2025)

    Fulltext@MSK | Save